Pub Date : 2025-06-01Epub Date: 2025-05-14DOI: 10.1016/j.imj.2025.100182
Lei Wang , Xuan Yao , Fei He , Jing Lv , Haijian Zhou , Quwen Li
As well known, the species of Bordetella, such as Bordetella pertussis and Bordetella parapertussis are prevalent respiratory tract pathogens. Bordetella hinzii, another species of Bordetella genus, Bordetella hinzii could cause meningitis, bacteremia, lung disease, endocarditis, chronic cholangitis and soft tissue abscess. In this study, we reported a new case of Bordetella hinzii infection in Asia with the clinical presentation and laboratory diagnosis. This study systematically analyzed the etiological characteristics of the pathogen using Vitek 2, MALDI-TOF MS, drug susceptibility testing, and whole-genome sequencing, aiming to provide a valuable reference for the diagnosis and treatment of Bordetella hinzii infection.
{"title":"Pneumonia caused by Bordetella hinzii: A case report","authors":"Lei Wang , Xuan Yao , Fei He , Jing Lv , Haijian Zhou , Quwen Li","doi":"10.1016/j.imj.2025.100182","DOIUrl":"10.1016/j.imj.2025.100182","url":null,"abstract":"<div><div>As well known, the species of Bordetella, such as <em>Bordetella pertussis</em> and <em>Bordetella parapertussis</em> are prevalent respiratory tract pathogens. <em>Bordetella hinzii</em>, another species of Bordetella genus, <em>Bordetella hinzii</em> could cause meningitis, bacteremia, lung disease, endocarditis, chronic cholangitis and soft tissue abscess. In this study, we reported a new case of <em>Bordetella hinzii</em> infection in Asia with the clinical presentation and laboratory diagnosis. This study systematically analyzed the etiological characteristics of the pathogen using Vitek 2, MALDI-TOF MS, drug susceptibility testing, and whole-genome sequencing, aiming to provide a valuable reference for the diagnosis and treatment of <em>Bordetella hinzii</em> infection<em>.</em></div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 2","pages":"Article 100182"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144213301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zoonotic diseases, which constitute 60% of all human infectious diseases, present substantial risks to public health, economies, and livelihoods. These diseases emerge at the human-animal-environment interface, with occupational exposure representing a critical yet underexamined dimension of zoonotic risk. Workers in high-risk sectors such as agriculture, wildlife management, and laboratory research face elevated exposure to zoonotic pathogens, often under conditions of inadequate preventive measures and resource constraints. Neurological disorders resulting from zoonotic infections, including Guillain-Barré syndrome, encephalitis, and meningitis, illustrate the severe health consequences for occupational groups. Cases linked to swine hepatitis E virus, West Nile virus, Streptococcus suis, and Baylisascaris procyonis underscore the urgent need for robust surveillance and targeted interventions.
The Ecohealth approach, integrated with the One Health framework, provides a transformative model for managing zoonotic risks by addressing the upstream drivers of disease emergence. By emphasizing environmental stewardship, ecological balance, and socio-economic equity, Ecohealth fosters sustainable preventive strategies. Occupational medicine is crucial in linking workplace safety with public health through tailored risk management, enhanced surveillance, and targeted education.
Despite these frameworks, significant barriers persist, including data gaps, underreporting of occupational diseases, and insufficient coordination among health sectors. Addressing these challenges requires implementing standardized occupational health surveillance systems, enhancing reporting mechanisms through digital tools, and promoting cross-sectoral data-sharing initiatives. Successful models, such as sentinel surveillance programs in agricultural sectors and integrated biosurveillance networks, demonstrate the feasibility of these strategies. Leveraging these approaches can facilitate early detection, improve reporting accuracy, and support evidence-based interventions.
{"title":"Occupational zoonoses, neurological diseases, and public health: A one health approach","authors":"Angela Stufano , Valentina Schino , Domenico Plantone , Guglielmo Lucchese","doi":"10.1016/j.imj.2025.100184","DOIUrl":"10.1016/j.imj.2025.100184","url":null,"abstract":"<div><div>Zoonotic diseases, which constitute 60% of all human infectious diseases, present substantial risks to public health, economies, and livelihoods. These diseases emerge at the human-animal-environment interface, with occupational exposure representing a critical yet underexamined dimension of zoonotic risk. Workers in high-risk sectors such as agriculture, wildlife management, and laboratory research face elevated exposure to zoonotic pathogens, often under conditions of inadequate preventive measures and resource constraints. Neurological disorders resulting from zoonotic infections, including Guillain-Barré syndrome, encephalitis, and meningitis, illustrate the severe health consequences for occupational groups. Cases linked to swine hepatitis E virus, West Nile virus, <em>Streptococcus suis</em>, and <em>Baylisascaris procyonis</em> underscore the urgent need for robust surveillance and targeted interventions.</div><div>The Ecohealth approach, integrated with the One Health framework, provides a transformative model for managing zoonotic risks by addressing the upstream drivers of disease emergence. By emphasizing environmental stewardship, ecological balance, and socio-economic equity, Ecohealth fosters sustainable preventive strategies. Occupational medicine is crucial in linking workplace safety with public health through tailored risk management, enhanced surveillance, and targeted education.</div><div>Despite these frameworks, significant barriers persist, including data gaps, underreporting of occupational diseases, and insufficient coordination among health sectors. Addressing these challenges requires implementing standardized occupational health surveillance systems, enhancing reporting mechanisms through digital tools, and promoting cross-sectoral data-sharing initiatives. Successful models, such as sentinel surveillance programs in agricultural sectors and integrated biosurveillance networks, demonstrate the feasibility of these strategies. Leveraging these approaches can facilitate early detection, improve reporting accuracy, and support evidence-based interventions.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 2","pages":"Article 100184"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-04-25DOI: 10.1016/j.imj.2025.100180
Yuanchao Xue, Filipe M. Cerqueira, Heather L. Stevenson, Natalie Williams-Bouyer, Rong Fang
Pyogenic liver abscess (PLA) is a potentially life-threatening disease. Early diagnosis and appropriate treatment are crucial to ensure high-quality healthcare for patients with PLA. However, this is complicated by their non-specific clinical symptoms. In addition, the etiologic organisms responsible for PLA are frequently culture-negative, thus complicating clinical decision-making. Here, we report a case of PLA caused by Streptococcus intermedius, as identified via DNA metagenomic sequencing of plasma.
{"title":"Culture-negative liver abscess identified with plasma microbial cell-free DNA sequencing: A case report","authors":"Yuanchao Xue, Filipe M. Cerqueira, Heather L. Stevenson, Natalie Williams-Bouyer, Rong Fang","doi":"10.1016/j.imj.2025.100180","DOIUrl":"10.1016/j.imj.2025.100180","url":null,"abstract":"<div><div>Pyogenic liver abscess (PLA) is a potentially life-threatening disease. Early diagnosis and appropriate treatment are crucial to ensure high-quality healthcare for patients with PLA. However, this is complicated by their non-specific clinical symptoms. In addition, the etiologic organisms responsible for PLA are frequently culture-negative, thus complicating clinical decision-making. Here, we report a case of PLA caused by <em>Streptococcus intermedius,</em> as identified via DNA metagenomic sequencing of plasma.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 2","pages":"Article 100180"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Oropouche virus (OROV) is a new zoonotic arbovirus that mostly affects Brazil and nearby countries. Since its discovery in 1955, it has caused more than 500,000 infections, with symptoms ranging from fever and headache to serious neuroinvasive disorders such as meningitis and encephalitis. The virus spreads through urban and sylvatic cycles via vectors such as Culicoides midges and Culex mosquitos, with humans and some vertebrates serving as amplifying hosts. The manuscript aims to analyze the transmission dynamics, clinical manifestations, diagnostic approaches, and potential preventive strategies for OROV. OROV is becoming an increasing health concern due to its global expansion and potential for serious consequences. Its growing threat, especially in light of the possibility of congenital abnormalities, is highlighted by the first recorded deaths in 2024 and the verification of vertical transmission. Clinical symptoms overlap greatly with other arboviruses, limiting early diagnosis; nonetheless, molecular approaches such as RT-PCR are crucial for identification. The current therapy is restricted to symptom control, highlighting the critical need for effective vaccinations. Live attenuated vaccination candidates and innovative techniques based on reverse genetics systems are both promising discoveries. However, the genetic variety of OROV strains poses obstacles to obtaining broad protection. To combat OROV, improved surveillance, strong public health initiatives, and quick vaccine development are needed. Public education and sustainable vector control are also essential for controlling outbreaks and lessening the virus effects.
{"title":"Mysterious Oropouche virus: Transmission, symptoms, and control","authors":"Sejal Porwal , Rishabha Malviya , Sathvik Belagodu Sridhar , Javedh Shareef , Tarun Wadhwa","doi":"10.1016/j.imj.2025.100177","DOIUrl":"10.1016/j.imj.2025.100177","url":null,"abstract":"<div><div>The Oropouche virus (OROV) is a new zoonotic arbovirus that mostly affects Brazil and nearby countries. Since its discovery in 1955, it has caused more than 500,000 infections, with symptoms ranging from fever and headache to serious neuroinvasive disorders such as meningitis and encephalitis. The virus spreads through urban and sylvatic cycles via vectors such as <em>Culicoides</em> midges and <em>Culex</em> mosquitos, with humans and some vertebrates serving as amplifying hosts. The manuscript aims to analyze the transmission dynamics, clinical manifestations, diagnostic approaches, and potential preventive strategies for OROV. OROV is becoming an increasing health concern due to its global expansion and potential for serious consequences. Its growing threat, especially in light of the possibility of congenital abnormalities, is highlighted by the first recorded deaths in 2024 and the verification of vertical transmission. Clinical symptoms overlap greatly with other arboviruses, limiting early diagnosis; nonetheless, molecular approaches such as RT-PCR are crucial for identification. The current therapy is restricted to symptom control, highlighting the critical need for effective vaccinations. Live attenuated vaccination candidates and innovative techniques based on reverse genetics systems are both promising discoveries. However, the genetic variety of OROV strains poses obstacles to obtaining broad protection. To combat OROV, improved surveillance, strong public health initiatives, and quick vaccine development are needed. Public education and sustainable vector control are also essential for controlling outbreaks and lessening the virus effects.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 2","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143815341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-04-29DOI: 10.1016/j.imj.2025.100181
Xinbei Jia , Linglong Wan , Fei Xiao , Xiaolan Huang , Juan Zhou , Yi Wang , Jun Tai
Background
Human adenovirus type 3 (HAdV-3) and 7 (HAdV-7) are significant causative agents of acute respiratory tract infections that are prevalent among school-based outbreaks across China. Rapid and accurate diagnosis is crucial for effective control and treatment of HAdV infection.
Methods
Here, we developed a novel diagnostic assay combining multiple cross displacement amplification (MCDA) with CRISPR-Cas12b technology, designated HAdV-MCDA-CRISPR, to rapidly detect HAdV-3 and HAdV-7. The assay targets a highly conserved region of the hexon gene, enabling broad detection of these serotypes. The protocol includes DNA extraction (15 minutes), MCDA amplification (40 minutes), and CRISPR detection (5 minutes), and is completed within one hour. Specificity was validated by testing against non-HAdV pathogens, while sensitivity was assessed using serial dilutions of hexon-containing plasmid DNA. Clinical performance was evaluated using 88 patient samples.
Results
The HAdV-MCDA-CRISPR assay demonstrated high sensitivity, detecting as little as 5 fg HAdV plasmid DNA per reaction, and showed no cross-reactivity with other common respiratory pathogens. Clinical validation using 88 patient samples further demonstrated the diagnostic accuracy of HAdV-MCDA-CRISPR.
Conclusions
HAdV-MCDA-CRISPR is a rapid, sensitive, and specific tool for diagnosing HAdV-3 and HAdV-7 infections, offering potential for timely clinical intervention and enhanced epidemiological surveillance.
{"title":"Rapid and sensitive detection of human adenovirus types 3 and 7 using CRISPR-Cas12b coupled with multiple cross displacement amplification","authors":"Xinbei Jia , Linglong Wan , Fei Xiao , Xiaolan Huang , Juan Zhou , Yi Wang , Jun Tai","doi":"10.1016/j.imj.2025.100181","DOIUrl":"10.1016/j.imj.2025.100181","url":null,"abstract":"<div><h3>Background</h3><div>Human adenovirus type 3 (HAdV-3) and 7 (HAdV-7) are significant causative agents of acute respiratory tract infections that are prevalent among school-based outbreaks across China. Rapid and accurate diagnosis is crucial for effective control and treatment of HAdV infection.</div></div><div><h3>Methods</h3><div>Here, we developed a novel diagnostic assay combining multiple cross displacement amplification (MCDA) with CRISPR-Cas12b technology, designated HAdV-MCDA-CRISPR, to rapidly detect HAdV-3 and HAdV-7. The assay targets a highly conserved region of the hexon gene, enabling broad detection of these serotypes. The protocol includes DNA extraction (15 minutes), MCDA amplification (40 minutes), and CRISPR detection (5 minutes), and is completed within one hour. Specificity was validated by testing against non-HAdV pathogens, while sensitivity was assessed using serial dilutions of hexon-containing plasmid DNA. Clinical performance was evaluated using 88 patient samples.</div></div><div><h3>Results</h3><div>The HAdV-MCDA-CRISPR assay demonstrated high sensitivity, detecting as little as 5 fg HAdV plasmid DNA per reaction, and showed no cross-reactivity with other common respiratory pathogens. Clinical validation using 88 patient samples further demonstrated the diagnostic accuracy of HAdV-MCDA-CRISPR.</div></div><div><h3>Conclusions</h3><div>HAdV-MCDA-CRISPR is a rapid, sensitive, and specific tool for diagnosing HAdV-3 and HAdV-7 infections, offering potential for timely clinical intervention and enhanced epidemiological surveillance.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 2","pages":"Article 100181"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-16DOI: 10.1016/j.imj.2024.100152
Yixin Liu , Xugang Wang , Qi Li , Shuo Zhu , Wenjing Zhu , Huanchun Chen , Youhui Si , Bibo Zhu , Shengbo Cao , Zikai Zhao , Jing Ye
{"title":"Corrigendum to “Screening a neurotransmitter-receptor-related inhibitor library identifies clomipramine HCl as a potential antiviral compound against Japanese encephalitis virus” [Infectious Medicine 3 (2024) 100130]","authors":"Yixin Liu , Xugang Wang , Qi Li , Shuo Zhu , Wenjing Zhu , Huanchun Chen , Youhui Si , Bibo Zhu , Shengbo Cao , Zikai Zhao , Jing Ye","doi":"10.1016/j.imj.2024.100152","DOIUrl":"10.1016/j.imj.2024.100152","url":null,"abstract":"","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 1","pages":"Article 100152"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eastern equine encephalitis virus (EEEV) is a lethal Alphavirus transmitted by Culiseta melanura mosquitoes that primarily cycles between birds. Although rare, infections in humans and horses are associated with high mortality rates and severe neurological effects. Climate change appears to be increasing the spread of this virus. This study aims to provide a comprehensive analysis of EEEV, including its transmission dynamics, pathogenesis, induced host immune response, and long-term impacts on survivors. It also highlights the virus's unique immune evasion strategies that complicate disease management and contribute to severe clinical outcomes, such as encephalitis with fever, convulsions, and coma. Survivors often face chronic cognitive, motor, and psychosocial impairments. Despite these significant public health risks, gaps remain in understanding the molecular mechanisms underlying immune evasion and the long-term neurological sequelae in survivors. By collating current knowledge, this review underscores the urgent need for the development of targeted vaccines and therapeutic interventions to mitigate the growing threat of EEEV, particularly in the context of climate change-driven geographical expansion.
{"title":"Eastern equine encephalitis virus: Pathogenesis, immune response, and clinical manifestations","authors":"Bhumika Parashar , Rishabha Malviya , Sathvik Belagodu Sridhar , Tarun Wadhwa , Sirajunisa Talath , Javedh Shareef","doi":"10.1016/j.imj.2025.100167","DOIUrl":"10.1016/j.imj.2025.100167","url":null,"abstract":"<div><div>Eastern equine encephalitis virus (EEEV) is a lethal <em>Alphavirus</em> transmitted by <em>Culiseta melanura</em> mosquitoes that primarily cycles between birds. Although rare, infections in humans and horses are associated with high mortality rates and severe neurological effects. Climate change appears to be increasing the spread of this virus. This study aims to provide a comprehensive analysis of EEEV, including its transmission dynamics, pathogenesis, induced host immune response, and long-term impacts on survivors. It also highlights the virus's unique immune evasion strategies that complicate disease management and contribute to severe clinical outcomes, such as encephalitis with fever, convulsions, and coma. Survivors often face chronic cognitive, motor, and psychosocial impairments. Despite these significant public health risks, gaps remain in understanding the molecular mechanisms underlying immune evasion and the long-term neurological sequelae in survivors. By collating current knowledge, this review underscores the urgent need for the development of targeted vaccines and therapeutic interventions to mitigate the growing threat of EEEV, particularly in the context of climate change-driven geographical expansion.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 1","pages":"Article 100167"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-02-05DOI: 10.1016/j.imj.2025.100168
Omor Faruk , Zilhas Ahmed Jewel , Sanjoy Bairagi , Mohammad Rasheduzzaman , Hindol Bagchi , Akber Subahan Mahbub Tuha , Imran Hossain , Ayon Bala , Sarafat Ali
Phages, including the viruses that lyse bacterial pathogens, offer unique therapeutic advantages, including their capacity to lyse antibiotic-resistant bacteria and disrupt biofilms without harming the host microbiota. The lack of new effective antibiotics and the growing limitations of existing antibiotics have refocused attention on phage therapy as an option in complex clinical cases such as burn wounds, cystic fibrosis, and pneumonia. This review describes clinical cases and preclinical studies in which phage therapy has been effective in both human and veterinary medicine, and in an agricultural context. In addition, critical challenges, such as the narrow host range of bacteriophages, the possibility of bacterial resistance, and regulatory constraints on the widespread use of phage therapy, are addressed. Future directions include optimizing phage therapy through strategies ranging from phage cocktails to broadening phage host range through genetic modification, and using phages as vaccines or biocontrol agents. In the future, if phage can be efficiently delivered, maintained in a stable state, and phage–antibiotic synergy can be achieved, phage therapy will offer much needed treatment options. However, the successful implementation of phage therapy within the current standards of practice will also require the considerable development of regulatory infrastructure and greater public acceptance. In closing, this review highlights the promise of phage therapy as a critical backup or substitute for antibiotics. It proposes a new role as a significant adjunct to, or even replacement for, antibiotics in treating multidrug-resistant bacterial infections.
{"title":"Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: The current status and future prospects","authors":"Omor Faruk , Zilhas Ahmed Jewel , Sanjoy Bairagi , Mohammad Rasheduzzaman , Hindol Bagchi , Akber Subahan Mahbub Tuha , Imran Hossain , Ayon Bala , Sarafat Ali","doi":"10.1016/j.imj.2025.100168","DOIUrl":"10.1016/j.imj.2025.100168","url":null,"abstract":"<div><div>Phages, including the viruses that lyse bacterial pathogens, offer unique therapeutic advantages, including their capacity to lyse antibiotic-resistant bacteria and disrupt biofilms without harming the host microbiota. The lack of new effective antibiotics and the growing limitations of existing antibiotics have refocused attention on phage therapy as an option in complex clinical cases such as burn wounds, cystic fibrosis, and pneumonia. This review describes clinical cases and preclinical studies in which phage therapy has been effective in both human and veterinary medicine, and in an agricultural context. In addition, critical challenges, such as the narrow host range of bacteriophages, the possibility of bacterial resistance, and regulatory constraints on the widespread use of phage therapy, are addressed. Future directions include optimizing phage therapy through strategies ranging from phage cocktails to broadening phage host range through genetic modification, and using phages as vaccines or biocontrol agents. In the future, if phage can be efficiently delivered, maintained in a stable state, and phage–antibiotic synergy can be achieved, phage therapy will offer much needed treatment options. However, the successful implementation of phage therapy within the current standards of practice will also require the considerable development of regulatory infrastructure and greater public acceptance. In closing, this review highlights the promise of phage therapy as a critical backup or substitute for antibiotics. It proposes a new role as a significant adjunct to, or even replacement for, antibiotics in treating multidrug-resistant bacterial infections.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 1","pages":"Article 100168"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To assess the enduring protective efficacy of the recombinant human papilloma virus (HPV) 16/18 bivalent vaccine (produced in Escherichia coli) in preventing HPV infection.
Methods
A long-term follow-up study was conducted in Xinmi, Henan Province, in September 2022, 9 years post-administration of the initial vaccine dose. This study was grounded in the phase III clinical trial of the vaccine (NCT01735006). Participants were recalled to collect exfoliated cervical cells for HPV DNA genotyping. The long-term protective efficacy of the vaccine against HPV infection was evaluated using Poisson distribution.
Results
A total of 1 123 volunteers were recalled, comprising 558 individuals in the experimental group and 565 in the control group, with mean ages of 30.80 ± 7.33 years and 30.64 ± 7.51 years, respectively. At baseline (0 days before vaccination), 147 participants (13.09%) were infected with any type of HPV. By the ninth year of follow-up, the overall HPV infection rate within the entire cohort had increased to 16.65%. In the intention-to-treat analysis, the demonstrated protective efficacy against HPV-16, HPV-18, and HPV-16/18 was 83.12% (95% confidence interval [CI]: 24.20–98.17), 100.00% (95% CI: −10.50 to 100.00) and 87.34% (95% CI: 46.17–98.59), respectively. In the modified intention-to-treat analysis, the protective efficacy of the vaccine against HPV-16, HPV-18, and HPV-16/18 was 82.90% (95% CI: 23.20–98.14), 100.00% (−10.71 to 100.00), and 87.36% (95% CI: 46.20–98.59), respectively.
Conclusions
Vaccination with the bivalent HPV vaccine offers long-term protection against HPV-16/18 infections for at least 9 years.
{"title":"Long-term protective efficacy of the Escherichia coli-produced HPV-16/18 bivalent human papillomavirus vaccine in women vaccinated at 18–45 years: A 9-year follow-up study","authors":"Xinhua Jia , Shangying Hu , Xuefeng Kuang , Youlin Qiao","doi":"10.1016/j.imj.2025.100164","DOIUrl":"10.1016/j.imj.2025.100164","url":null,"abstract":"<div><h3>Background</h3><div>To assess the enduring protective efficacy of the recombinant human papilloma virus (HPV) 16/18 bivalent vaccine (produced in <em>Escherichia coli</em>) in preventing HPV infection.</div></div><div><h3>Methods</h3><div>A long-term follow-up study was conducted in Xinmi, Henan Province, in September 2022, 9 years post-administration of the initial vaccine dose. This study was grounded in the phase III clinical trial of the vaccine (NCT01735006). Participants were recalled to collect exfoliated cervical cells for HPV DNA genotyping. The long-term protective efficacy of the vaccine against HPV infection was evaluated using Poisson distribution.</div></div><div><h3>Results</h3><div>A total of 1 123 volunteers were recalled, comprising 558 individuals in the experimental group and 565 in the control group, with mean ages of 30.80 ± 7.33 years and 30.64 ± 7.51 years, respectively. At baseline (0 days before vaccination), 147 participants (13.09%) were infected with any type of HPV. By the ninth year of follow-up, the overall HPV infection rate within the entire cohort had increased to 16.65%. In the intention-to-treat analysis, the demonstrated protective efficacy against HPV-16, HPV-18, and HPV-16/18 was 83.12% (95% confidence interval [CI]: 24.20–98.17), 100.00% (95% CI: −10.50 to 100.00) and 87.34% (95% CI: 46.17–98.59), respectively. In the modified intention-to-treat analysis, the protective efficacy of the vaccine against HPV-16, HPV-18, and HPV-16/18 was 82.90% (95% CI: 23.20–98.14), 100.00% (−10.71 to 100.00), and 87.36% (95% CI: 46.20–98.59), respectively.</div></div><div><h3>Conclusions</h3><div>Vaccination with the bivalent HPV vaccine offers long-term protection against HPV-16/18 infections for at least 9 years.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 1","pages":"Article 100164"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143464198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号